BioSpace News Archive

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has changed its corporate name from Vincera Pharma, Inc. to Vincerx, Inc. The Company’s common stock, units and warrants will continue to trade under the current ticker symbols, “VINC,” “VINCW” and “VINCU,” respectively. About Vincerx, Inc. Vi

The double-blind, placebo-controlled investigator-initiated CYstic fibrosis PHage study at Yale (CYPHY) will assess the safety and efficacy of phage therapy YPT-01 against chronic Pseudomonas aeruginosa infections

MYND Life Sciences Inc. a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce the closing of a non-brokered private placement offering by the Company of an aggregate of 8,000,000 common shares at a price of CDN$0.30 per Common Share for aggregate gross proceeds of CDN$2.4 million.

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Doug Murphy-Chutorian , and chief marketing officer, Dennis Rosenberg , will present a company overview at the H.C.